Network Pharmacology and Molecular Docking Analysis Reveal Insights into the Molecular Mechanism of Shengma-Gegen Decoction on Monkeypox
Abstract
:1. Introduction
2. Materials and Methods
2.1. Screen of SMGGD Bioactive Compounds
2.2. Target Genes Related to Bioactive Compounds
2.3. The Specific Genes of Monkeypox
2.4. Monkeypox Specific Genes Related to Active Compounds of SMGGD
2.5. Network Construction
2.5.1. The Construction of the Pharmacological Network
2.5.2. Construction of Protein–Protein Interaction (PPI) Network and Screening of Core Targets
2.5.3. Construction of TCM-Bioactive Compound-Hub Genes Network
2.6. Gene Ontology (GO) Functional Annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Analysis
2.7. Molecular Docking between Compounds and Targets
- Preparation of receptors: The 3D structure of 8 hub targets (receptors) were obtained from the RCSBPDB database (https://www.rcsb.org/, accessed on 4 October 2022) and saved in PDB format. The obtained 3D structures (PDB format) were further processed by removing water molecules (command of “remove solvent”) and the ligand (command of “remove organic”) using PyMOL sofware (version 2.2.0).
- Preparation of ligands: 2D structure files (SDF format) of active compounds were downloaded from the PubChem website (https://pubchem.ncbi.nlm.nih.gov/, accessed on 4 October 2022) [30]. Then, the files were converted into PDB format using Open Babel software (version 2.4.1).
- Molecular docking: Hydrogen and Gasteiger charges were added to the above receptors and ligands using ADT software before they were saved in PDBQT format. The AutoGrid Tool of the ADT software was used to set the docking frame parameters including setting the grid box containing the entire receptor. The parameter was set as the Lamarckian genetic algorithm (LGA) to generate 10 docking results for each ligand with the corresponding receptor. All of the docking results were visualized via PyMOL software.
3. Results
3.1. SMGGD Bioactive Compounds and Related Targets Selection
3.2. Compound Target Network and Compound Target Disease Network
3.3. GO and KEGG Enrichment Analysis
3.4. Molecular Docking
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cho, C.T.; Wenner, H.A. Monkeypox virus. Bacteriol. Rev. 1973, 37, 1–18. [Google Scholar] [CrossRef]
- Thornhill, J.P.; Barkati, S.; Walmsley, S.; Rockstroh, J.; Antinori, A.; Harrison, L.B.; Palich, R.; Nori, A.; Reeves, I.; Habibi, M.S. Monkeypox virus infection in humans across 16 countries—April–June 2022. N. Engl. J. Med. 2022, 387, 679–691. [Google Scholar] [CrossRef] [PubMed]
- Bhattacharya, M.; Dhama, K.; Chakraborty, C. Recently spreading human monkeypox virus infection and its transmission during COVID-19 pandemic period: A travelers’ prospective. Travel Med. Infect. Dis. 2022, 49, 102398. [Google Scholar] [CrossRef] [PubMed]
- Minhaj, F.S.; Ogale, Y.P.; Whitehill, F.; Schultz, J.; Foote, M.; Davidson, W.; Hughes, C.M.; Wilkins, K.; Bachmann, L.; Chatelain, R. Monkeypox outbreak—Nine states, May 2022. Morb. Mortal. Wkly. Rep. 2022, 71, 764. [Google Scholar] [CrossRef] [PubMed]
- Philpott, D. Epidemiologic and clinical characteristics of monkeypox cases—United States, 17 May–22 July 2022. Morb. Mortal. Wkly. Rep. 2022, 71, 1018–1022. [Google Scholar] [CrossRef] [PubMed]
- Yang, Z. Monkeypox: A potential global threat? J. Med. Virol. 2022, 94, 4034–4036. [Google Scholar] [CrossRef]
- WHO. 2022 Monkeypox Outbreak: Global Trends. Available online: https://worldhealthorg.shinyapps.io/mpx_global/ (accessed on 6 October 2022).
- Newsroom, C. CDC and Health Partners Responding to Monkeypox Case in the US. Available online: https://www.cdc.gov/media/releases/2022/s0518-monkeypox-case.html (accessed on 6 October 2022).
- Monkeypox—Signs and Symptoms. Available online: https://www.cdc.gov/poxvirus/monkeypox/symptoms/index.html (accessed on 6 October 2022).
- Fine, P.; Jezek, Z.; Grab, B.; Dixon, H. The transmission potential of monkeypox virus in human populations. Int. J. Epidemiol. 1988, 17, 643–650. [Google Scholar] [CrossRef]
- Desai, A.N.; Thompson, G.R.; Neumeister, S.M.; Arutyunova, A.M.; Trigg, K.; Cohen, S.H. Compassionate use of tecovirimat for the treatment of monkeypox infection. JAMA 2022, 328, 1348–1350. [Google Scholar] [CrossRef]
- Warner, B.M.; Klassen, L.; Sloan, A.; Deschambault, Y.; Soule, G.; Banadyga, L.; Cao, J.; Strong, J.E.; Kobasa, D.; Safronetz, D. In vitro and in vivo efficacy of Tecovirimat against a recently emerged 2022 Monkeypox virus isolate. Sci. Transl. Med. 2022, eade7646. [Google Scholar] [CrossRef]
- YL, J. The transmission potential of monkeypox virus in human populations. Int. J. Tradit. Chin. Med. 1995, 31, 643–650. (In Chinese) [Google Scholar]
- Wang, K.-C.; Chang, J.-S.; Chiang, L.-C.; Lin, C.-C. Sheng-Ma-Ge-Gen-Tang (Shoma-kakkon-to) inhibited cytopathic effect of human respiratory syncytial virus in cell lines of human respiratory tract. J. Ethnopharmacol. 2011, 135, 538–544. [Google Scholar] [CrossRef] [PubMed]
- YB, Z. Treatment of 300 cases of hepatitis B with Shengma Gegen Decoction. Clin. J. Tradit. Chin. Med. 1997, 9, 252. [Google Scholar]
- National Health Commission. Diagnosis and Treatment Guideline of Monkeypox. Infect. Dis. Info. 2022, 35, 193–194. [Google Scholar]
- Hopkins, A.L. Network pharmacology. Nat. Biotechnol. 2007, 25, 1110–1111. [Google Scholar] [CrossRef]
- Chen, W.; Da, W.; Li, C.; Fan, H.; Liang, R.; Yuan, J.; Huang, X.; Yang, R.; Zhang, J.; Zhu, J. Network pharmacology-based identification of the protective mechanisms of taraxasterol in experimental colitis. Int. Immunopharmacol. 2019, 71, 259–266. [Google Scholar] [CrossRef]
- Lim, H.; Xie, L. Omics data integration and analysis for systems pharmacology. In Bioinformatics and Drug Discovery; Springer: Berlin/Heidelberg, Germany, 2019; pp. 199–214. [Google Scholar]
- Ru, J.; Li, P.; Wang, J.; Zhou, W.; Li, B.; Huang, C.; Li, P.; Guo, Z.; Tao, W.; Yang, Y. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform. 2014, 6, 13. [Google Scholar] [CrossRef] [Green Version]
- Breuza, L.; Poux, S.; Estreicher, A.; Famiglietti, M.L.; Magrane, M.; Tognolli, M.; Bridge, A.; Baratin, D.; Redaschi, N.; Consortium, U. Te UniProtKB guide to the human proteome. Database 2016, 2016, 120. [Google Scholar] [CrossRef] [Green Version]
- Yu, G.; Wang, L.-G.; Han, Y.; He, Q.-Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 2012, 16, 284–287. [Google Scholar] [CrossRef]
- Stelzer, G.; Rosen, N.; Plaschkes, I.; Zimmerman, S.; Twik, M.; Fishilevich, S.; Stein, T.I.; Nudel, R.; Lieder, I.; Mazor, Y. The GeneCards suite: From gene data mining to disease genome sequence analyses. Curr. Protoc. Bioinform. 2016, 54, 1.30.1–1.30.33. [Google Scholar] [CrossRef]
- Wishart, D.S.; Feunang, Y.D.; Guo, A.C.; Lo, E.J.; Marcu, A.; Grant, J.R.; Sajed, T.; Johnson, D.; Li, C.; Sayeeda, Z. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 2018, 46, D1074–D1082. [Google Scholar] [CrossRef]
- Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019, 47, D607–D613. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chin, C. Identifying Hub Objects and Sub-Networks From Complex Interactome. BMC Syst. Biol. 2014, 8 (Suppl. 4), S11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meng, Z.; Liu, X.; Wu, J.; Zhou, W.; Wang, K.; Jing, Z.; Liu, S.; Ni, M.; Zhang, X. Mechanisms of compound kushen injection for the treatment of lung cancer based on network pharmacology. Evid. -Based Complement. Altern. Med. 2019, 2019, 4637839. [Google Scholar] [CrossRef] [PubMed]
- Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739–1749. [Google Scholar] [CrossRef]
- Mehta, P.; Miszta, P.; Filipek, S. Molecular modeling of histamine receptors—Recent advances in drug discovery. Molecules 2021, 26, 1778. [Google Scholar] [CrossRef]
- Kim, S.; Thiessen, P.A.; Bolton, E.E.; Chen, J.; Fu, G.; Gindulyte, A.; Han, L.; He, J.; He, S.; Shoemaker, B.A. PubChem substance and compound databases. Nucleic Acids Res. 2016, 44, D1202–D1213. [Google Scholar] [CrossRef] [PubMed]
- Qu, L.; Song, K.; Zhang, Q.; Guo, J.; Huang, J. Simultaneous determination of six isoflavones from puerariae lobatae radix by cpe-hplc and effect of puerarin on tyrosinase activity. Molecules 2020, 25, 344. [Google Scholar] [CrossRef] [Green Version]
- Fang, Z.; Moon, D.-C.; Son, K.-H.; Son, J.-K.; Min, B.-S.; Woo, M.-H. Quantitative and pattern recognition analyses for the quality evaluation of Cimicifugae Rhizoma by HPLC. Bull. Korean Chem. Soc. 2011, 32, 239–246. [Google Scholar] [CrossRef] [Green Version]
- Zhou, W.; Wang, J.; Wu, Z.; Huang, C.; Lu, A.; Wang, Y. Systems pharmacology exploration of botanic drug pairs reveals the mechanism for treating different diseases. Sci. Rep. 2016, 6, 36985. [Google Scholar] [CrossRef] [Green Version]
- Ai, H.; Wu, X.; Qi, M.; Zhang, L.; Hu, H.; Zhao, Q.; Zhao, J.; Liu, H. Study on the mechanisms of active compounds in traditional chinese medicine for the treatment of influenza virus by virtual screening. Interdiscip. Sci. Comput. Life Sci. 2018, 10, 320–328. [Google Scholar] [CrossRef]
- Tan, Y.-Q.; Chen, H.-W.; Li, J.; Wu, Q.-J. Efficacy, chemical constituents, and pharmacological actions of Radix Paeoniae Rubra and Radix Paeoniae Alba. Front. Pharmacol. 2020, 11, 1054. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.X.; Zeng, M.S.; Ye, Y.; Liu, J.Y.; Xu, P.P. Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase. Phytother. Res. 2021, 35, 324–336. [Google Scholar] [CrossRef] [PubMed]
- Wu, M.; Zhang, Q.; Yi, D.; Wu, T.; Chen, H.; Guo, S.; Li, S.; Ji, C.; Wang, L.; Zhao, D. Quantitative proteomic analysis reveals antiviral and anti-inflammatory effects of puerarin in piglets infected with porcine epidemic diarrhea virus. Front. Immunol. 2020, 11, 169. [Google Scholar] [CrossRef] [PubMed]
- He, Y.; Huang, M.; Tang, C.; Yue, Y.; Liu, X.; Zheng, Z.; Dong, H.; Liu, D. Dietary daidzein inhibits hepatitis C virus replication by decreasing microRNA-122 levels. Virus Res. 2021, 298, 198404. [Google Scholar] [CrossRef]
- Li, H.-Y.; Pan, L.; Ke, Y.-S.; Batnasan, E.; Jin, X.-Q.; Liu, Z.-Y.; Ba, X.-Q. Daidzein suppresses pro-inflammatory chemokine Cxcl2 transcription in TNF-α-stimulated murine lung epithelial cells via depressing PARP-1 activity. Acta Pharmacol. Sin. 2014, 35, 496–503. [Google Scholar] [CrossRef] [Green Version]
- Zhang, T.; Wu, Z.; Du, J.; Hu, Y.; Liu, L.; Yang, F.; Jin, Q. Anti-Japanese-encephalitis-viral effects of kaempferol and daidzin and their RNA-binding characteristics. PLoS ONE 2012, 7, e30259. [Google Scholar] [CrossRef] [Green Version]
- Kazmi, Z.; Zeeshan, S.; Khan, A.; Malik, S.; Shehzad, A.; Seo, E.K.; Khan, S. Anti-epileptic activity of daidzin in PTZ-induced mice model by targeting oxidative stress and BDNF/VEGF signaling. Neurotoxicology 2020, 79, 150–163. [Google Scholar] [CrossRef]
- Hirabayashi, T.; Ochiai, H.; Sakai, S.; Nakajima, K.; Terasawa, K. Inhibitory effect of ferulic acid and isoferulic acid on murine interleukin-8 production in response to influenza virus infections in vitro and in vivo. Planta Med. 1995, 61, 221–226. [Google Scholar] [CrossRef]
- Sakai, S.; Kawamata, H.; Kogure, T.; Mantani, N.; Terasawa, K.; Umatake, M.; Ochiai, H. Inhibitory effect of ferulic acid and isoferulic acid on the production of macrophage inflammatory protein-2 in response to respiratory syncytial virus infection in RAW264. 7 cells. Mediat. Inflamm. 1999, 8, 173–175. [Google Scholar] [CrossRef]
- Yu, W.; Zeng, M.; Xu, P.; Liu, J.; Wang, H. Effect of paeoniflorin on acute lung injury induced by influenza A virus in mice. Evidences of its mechanism of action. Phytomedicine 2021, 92, 153724. [Google Scholar] [CrossRef]
- Chiow, K.; Phoon, M.; Putti, T.; Tan, B.K.; Chow, V.T. Evaluation of antiviral activities of Houttuynia cordata Thunb. extract, quercetin, quercetrin and cinanserin on murine coronavirus and dengue virus infection. Asian Pac. J. Trop. Med. 2016, 9, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, W.; Li, R.; Li, X.; He, J.; Jiang, S.; Liu, S.; Yang, J. Quercetin as an antiviral agent inhibits influenza A virus (IAV) entry. Viruses 2015, 8, 6. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez, O.; Fontanes, V.; Raychaudhuri, S.; Loo, R.; Loo, J.; Arumugaswami, V.; Sun, R.; Dasgupta, A.; French, S.W. The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production. Hepatology 2009, 50, 1756–1764. [Google Scholar] [CrossRef]
- Bachmetov, L.; Gal-Tanamy, M.; Shapira, A.; Vorobeychik, M.; Giterman-Galam, T.; Sathiyamoorthy, P.; Golan-Goldhirsh, A.; Benhar, I.; Tur-Kaspa, R.; Zemel, R. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J. Viral Hepat. 2012, 19, e81–e88. [Google Scholar] [CrossRef]
- Mehrbod, P.; Hudy, D.; Shyntum, D.; Markowski, J.; Łos, M.J.; Ghavami, S. Quercetin as a natural therapeutic candidate for the treatment of influenza virus. Biomolecules 2020, 11, 10. [Google Scholar] [CrossRef] [PubMed]
- Schwarz, S.; Sauter, D.; Wang, K.; Zhang, R.; Sun, B.; Karioti, A.; Bilia, A.R.; Efferth, T.; Schwarz, W. Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus. Planta Med. 2014, 80, 177–182. [Google Scholar] [CrossRef] [Green Version]
- Kim, M.; Lim, S.J.; Kang, S.W.; Um, B.-H.; Nho, C.W. Aceriphyllum rossii extract and its active compounds, quercetin and kaempferol inhibit IgE-mediated mast cell activation and passive cutaneous anaphylaxis. J. Agric. Food Chem. 2014, 62, 3750–3758. [Google Scholar] [CrossRef] [PubMed]
- Abian, O.; Ortega-Alarcon, D.; Jimenez-Alesanco, A.; Ceballos-Laita, L.; Vega, S.; Reyburn, H.T.; Rizzuti, B.; Velazquez-Campoy, A. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int. J. Biol. Macromol. 2020, 164, 1693–1703. [Google Scholar] [CrossRef] [PubMed]
- Sun, X.; Zhang, Y.; Liu, Y.; Wang, G. Study on mechanism of Reduning Injection in treating novel coronavirus pneumonia based on network pharmacology. J. Chin. Med. Mater. 2020, 7, 1797–1798. [Google Scholar]
- Wang, L.; Yang, Z.; Zhang, H.; Yu, H.; Yang, K.; Fu, B.; Yang, H. Study on the network pharmacology and preliminary evidence of Lianhua Qingwen in the treatment of novel coronavirus (2019-nCoV) pneumonia. J. Chin. Med. Mater. 2020, 43, 772–778. [Google Scholar]
- Huang, Y.-F.; Bai, C.; He, F.; Xie, Y.; Zhou, H. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19). Pharmacol. Res. 2020, 158, 104939. [Google Scholar] [CrossRef] [PubMed]
- Zhu, L.; Wang, P.; Yuan, W.; Zhu, G. Kaempferol inhibited bovine herpesvirus 1 replication and LPS-induced inflammatory response. Acta. Virol. 2018, 62, 220–225. [Google Scholar] [CrossRef] [PubMed]
- Siegrist, E.A.; Sassine, J. Antivirals with activity against monkeypox: A clinically oriented review. Clin. Infect. Dis. 2022; ciac622, Online ahead of print. [Google Scholar] [CrossRef]
- Hammarlund, E.; Dasgupta, A.; Pinilla, C.; Norori, P.; Früh, K.; Slifka, M.K. Monkeypox virus evades antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation. Proc. Natl. Acad. Sci. USA 2008, 105, 14567–14572. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Whitney, J.B.; Asmal, M.; Geiben-Lynn, R. Serpin induced antiviral activity of prostaglandin synthetase-2 against HIV-1 replication. PLoS ONE 2011, 6, e18589. [Google Scholar] [CrossRef]
- Soni, K.K.; Meshram, D.; Lawal, T.O.; Patel, U.; Mahady, G.B. Fractions of Boswellia serrata suppress LTA4, LTC4, cyclooxygenase-2 activities and mRNA in HL-60 cells and reduce lung inflammation in BALB/c mice. Curr. Drug Discov. Technol. 2021, 18, 95–104. [Google Scholar] [CrossRef] [PubMed]
- Loganathan, T.; Ramachandran, S.; Shankaran, P.; Nagarajan, D. Host transcriptome-guided drug repurposing for COVID-19 treatment: A meta-analysis based approach. PeerJ 2020, 8, e9357. [Google Scholar] [CrossRef] [PubMed]
- Hop, H.T.; Arayan, L.T.; Huy, T.X.; Reyes, A.W.; Vu, S.H.; Min, W.; Lee, H.J.; Rhee, M.H.; Chang, H.H.; Kim, S. The key role of c-Fos for immune regulation and bacterial dissemination in Brucella infected macrophage. Front. Cell. Infect. Microbiol. 2018, 8, 287. [Google Scholar] [CrossRef] [PubMed]
- Subbarao, K.; Mahanty, S. Respiratory virus infections: Understanding COVID-19. Immunity 2020, 52, 905–909. [Google Scholar] [CrossRef]
- Noack, M.; Miossec, P. Selected cytokine pathways in rheumatoid arthritis. In Seminars in Immunopathology; Springer: Berlin/Heidelberg, Germany, 2017; pp. 365–383. [Google Scholar]
- Herbein, G.; O’brien, W.A. Tumor Necrosis Factor (TNF)–α and TNF Receptors in Viral Pathogenesis. Proc. Soc. Exp. Biol. Med. 2000, 223, 241–257. [Google Scholar] [CrossRef]
- García-Ramírez, R.A.; Ramirez-Venegas, A.; Quintana-Carrillo, R.; Camarena, Á.E.; Falfan-Valencia, R.; Mejía-Aranguré, J.M. TNF, IL6, and IL1B polymorphisms are associated with severe influenza A (H1N1) virus infection in the Mexican population. PLoS ONE 2015, 10, e0144832. [Google Scholar] [CrossRef] [Green Version]
- Iboshi, Y.; Nakamura, K.; Fukaura, K.; Iwasa, T.; Ogino, H.; Sumida, Y.; Ihara, E.; Akiho, H.; Harada, N.; Nakamuta, M. Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis. J. Gastroenterol. 2017, 52, 315–326. [Google Scholar] [CrossRef] [PubMed]
- Molesworth-Kenyon, S.J.; Yin, R.; Oakes, J.E.; Lausch, R.N. IL-17 receptor signaling influences virus-induced corneal inflammation. J. Leukoc. Biol. 2008, 83, 401–408. [Google Scholar] [CrossRef]
- Anipindi, V.C.; Bagri, P.; Roth, K.; Dizzell, S.E.; Nguyen, P.V.; Shaler, C.R.; Chu, D.K.; Jiménez-Saiz, R.; Liang, H.; Swift, S. Estradiol enhances CD4+ T-cell anti-viral immunity by priming vaginal DCs to induce Th17 responses via an IL-1-dependent pathway. PLoS Pathog. 2016, 12, e1005589. [Google Scholar]
- Andrade, A.A.; Silva, P.N.; Pereira, A.C.; De Sousa, L.P.; Ferreira, P.C.; Gazzinelli, R.T.; Kroon, E.G.; Ropert, C.; Bonjardim, C.A. The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication. Biochem. J. 2004, 381, 437–446. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hemonnot, B.; Cartier, C.; Gay, B.; Rebuffat, S.; Bardy, M.; Devaux, C.; Boyer, V.; Briant, L. The host cell MAP kinase ERK-2 regulates viral assembly and release by phosphorylating the p6gag protein of HIV-1. J. Biol. Chem. 2004, 279, 32426–32434. [Google Scholar] [CrossRef]
- Pei, R.; Zhang, X.; Xu, S.; Meng, Z.; Roggendorf, M.; Lu, M.; Chen, X. Regulation of hepatitis C virus replication and gene expression by the MAPK-ERK pathway. Virol. Sin. 2012, 27, 278–285. [Google Scholar] [CrossRef]
- Xuan, D.T.M.; Yeh, I.; Wu, C.-C.; Su, C.-Y.; Liu, H.-L.; Chiao, C.-C.; Ku, S.-C.; Jiang, J.-Z.; Sun, Z.; Ta, H.D.K. Comparison of Transcriptomic Signatures between Monkeypox-Infected Monkey and Human Cell Lines. J. Immunol. Res. 2022, 2022, 3883822. [Google Scholar] [CrossRef]
ID | Description | p Value | p Adjust | Targets |
---|---|---|---|---|
hsa05323 | Rheumatoid arthritis | 5.4469 × 10−11 | 6.1006 × 10−9 | FOS/ICAM1/IL1B/IL6/CCL2/VEGFA |
hsa04668 | TNF signaling pathway | 1.7026 × 10−10 | 9.5347 × 10−9 | FOS/ICAM1/IL1B/IL6/PTGS2/CCL2 |
hsa04657 | IL-17 signaling pathway | 1.0457 × 10−8 | 3.9039 × 10−7 | FOS/IL1B/IL6/PTGS2/CCL2 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.4316 × 10−8 | 4.0084 × 10−7 | ICAM1/IL1B/IL6/CCL2/VEGFA |
hsa05418 | Fluid shear stress and atherosclerosis | 7.5524 × 10−8 | 1.6683 × 10−6 | FOS/ICAM1/IL1B/CCL2/VEGFA |
hsa05144 | Malaria | 8.9372 × 10−8 | 1.6683 × 10−6 | ICAM1/IL1B/IL6/CCL2 |
hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.9113 × 10−7 | 6.2581 × 10−6 | FOS/ICAM1/IL6/PTGS2/VEGFA |
hsa05163 | Human cytomegalovirus infection | 8.4005 × 10-7 | 1.1761 × 10−5 | IL1B/IL6/PTGS2/CCL2/VEGFA |
hsa05142 | Chagas disease | 1.6153 × 10−6 | 2.0101 × 10−5 | FOS/IL1B/IL6/CCL2 |
hsa05143 | African trypanosomiasis | 4.8805 × 10−6 | 5.3595 × 10−5 | ICAM1/IL1B/IL6 |
hsa05135 | Yersinia infection | 5.2638 × 10−6 | 5.3595 × 10−5 | FOS/IL1B/IL6/CCL2 |
hsa05164 | Influenza A | 1.2715 × 10−5 | 0.00011867 | ICAM1/IL1B/IL6/CCL2 |
hsa05133 | Pertussis | 4.3361 × 10−5 | 0.00036078 | FOS/IL1B/IL6 |
hsa05140 | Leishmaniasis | 4.5098 × 10−5 | 0.00036078 | FOS/IL1B/PTGS2 |
hsa01521 | EGFR tyrosine kinase inhibitor resistance | 4.8708 × 10−5 | 0.00036368 | EGF/IL6/VEGFA |
hsa04010 | MAPK signaling pathway | 0.00010729 | 0.0006535 | EGF/FOS/IL1B/VEGFA |
hsa04064 | NF-kappa B signaling pathway | 0.00011086 | 0.0006535 | ICAM1/IL1B/PTGS2 |
hsa04620 | Toll-like receptor signaling pathway | 0.00011086 | 0.0006535 | FOS/IL1B/IL6 |
hsa04625 | C-type lectin receptor signaling pathway | 0.00011086 | 0.0006535 | IL1B/IL6/PTGS2 |
hsa04659 | Th17 cell differentiation | 0.00012066 | 0.00067572 | FOS/IL1B/IL6 |
Active Ingredients | Hub Targets | Pdb ID | Binding Energy (kcal/mol) | Hydrogen Bonds |
---|---|---|---|---|
paeoniflorin | IL6 | 4o9h | −13.05 | GLU46(A), ASP62(A), GLU99(A), PHE100(A) |
puerarin | PTGS2 | 5ikr | −12.05 | VAL228(A), GLN374(A), ASN375(A), GLY533(A), ASN537(A), VAL538(A) |
quercetin | PTGS2 | 5ikr | −9.62 | TYR373(A), GLY225(A), VAL228(A), GLY533(A), ASN537(A) |
daidzin | PTGS2 | 5ikr | −9.59 | ASN34(A), SER49(A), ALA132(A), GLY135(A), TRP323(A), GLY327(A), LYS459(A) |
puerarin | VEGFA | 1mjv | −9.08 | TYR25(A), GLY59(A), CYS61(A), GLU64(A), LYS107(A) |
daidzein | PTGS2 | 5ikrj | −8.85 | VAL228(A), GLN374(A), ASN375(A), GLY533(A), ASN537(A), VAL538(A) |
kaempferol | PTGS2 | 5ikr | −8.42 | VAL228(A), TYR373(A), ASN375(A), GLY533(A) |
quercetin | EGF | 1jl9 | −8.27 | PRO7(A), ASP11(A), CYS14(A), GLY18(A) |
quercetin | IL1B | 1hib | −8.07 | GLU25(A), PRO78(A), LEU80(A), VAL132(A), LEU134(A) |
quercetin | IL6 | 4o9h | −7.92 | LEU45(A), TRP47(A), ASP62(A), THR98(A), PHE100(A) |
puerarin | FOS | 1fos | −7.67 | LYS188(A), GLU191(A) |
daidzein | IL6 | 4o9h | −7.29 | LEU45(A), THP47(A), PHE100(A) |
kaempferol | ICAM1 | 2oz4 | −7.25 | ASP131(A), GLU222(A), ARG227(A), PRO228(A), LYS232(A) |
quercetin | CCL2 | 1dol | −6.81 | ALA4(A), ALA7(A), PRO8(A), THR10(A), THR32(A), SER33(A) |
daidzein | ICAM1 | 2oz4 | −6.69 | GLU284(A) |
quercetin | VEGFA | 1mjv | −6.66 | GLU42(A), TYR45(A), PHE47(A), SER50(A) |
quercetin | ICAM1 | 2oz4 | −6.29 | ILE-258(A), GLU-284(A), LYS-287(A) |
daidzein | VEGFA | 1mjv | −5.95 | CYS61(A), GLU64(A) |
isoferulic acid | PTGS2 | 5ikr | −5.71 | SER126(A), GLN372(A) |
quercetin | FOS | 1fos | −5.3 | LYS188(A), GLU189(A), GLU191(A), LYS192(A) |
daidzein | FOS | 1fos | −4.71 | GLU284 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dai, L.; Zhang, G.; Wan, X. Network Pharmacology and Molecular Docking Analysis Reveal Insights into the Molecular Mechanism of Shengma-Gegen Decoction on Monkeypox. Pathogens 2022, 11, 1342. https://doi.org/10.3390/pathogens11111342
Dai L, Zhang G, Wan X. Network Pharmacology and Molecular Docking Analysis Reveal Insights into the Molecular Mechanism of Shengma-Gegen Decoction on Monkeypox. Pathogens. 2022; 11(11):1342. https://doi.org/10.3390/pathogens11111342
Chicago/Turabian StyleDai, Liujiang, Guizhong Zhang, and Xiaochun Wan. 2022. "Network Pharmacology and Molecular Docking Analysis Reveal Insights into the Molecular Mechanism of Shengma-Gegen Decoction on Monkeypox" Pathogens 11, no. 11: 1342. https://doi.org/10.3390/pathogens11111342